138 related articles for article (PubMed ID: 23941824)
1. Production of human parvovirus 4 VP2 virus-like particles in yeast and their evaluation as an antigen for detection of virus-specific antibodies in human serum.
Tamošiūnas PL; Simutis K; Kodzė I; Firantienė R; Emužytė R; Petraitytė-Burneikienė R; Zvirblienė A; Sasnauskas K
Intervirology; 2013; 56(5):271-7. PubMed ID: 23941824
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of human bocaviruses and parvovirus 4 in solid tissues.
Norja P; Hedman L; Kantola K; Kemppainen K; Suvilehto J; Pitkäranta A; Aaltonen LM; Seppänen M; Hedman K; Söderlund-Venermo M
J Med Virol; 2012 Aug; 84(8):1267-73. PubMed ID: 22711355
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection.
Yang SJ; Hung CC; Chang SY; Lee KL; Chen MY
J Clin Virol; 2011 May; 51(1):64-7. PubMed ID: 21353629
[TBL] [Abstract][Full Text] [Related]
4. Yeast-generated virus-like particles as antigens for detection of human bocavirus 1-4 specific antibodies in human serum.
Tamošiūnas PL; Petraitytė-Burneikienė R; Bulavaitė A; Marcinkevičiūtė K; Simutis K; Lasickienė R; Firantienė R; Ėmužytė R; Žvirblienė A; Sasnauskas K
Appl Microbiol Biotechnol; 2016 Jun; 100(11):4935-46. PubMed ID: 26846623
[TBL] [Abstract][Full Text] [Related]
5. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
6. Antigenicity study of the yeast-generated human parvovirus 4 (PARV4) virus-like particles.
Lazutka J; Simutis K; Matulis P; Petraitytė-Burneikienė R; Kučinskaitė-Kodzė I; Simanavičius M; Tamošiunas PL
Virus Res; 2021 Jan; 292():198236. PubMed ID: 33242523
[TBL] [Abstract][Full Text] [Related]
7. Testing UK blood donors for exposure to human parvovirus 4 using a time-resolved fluorescence immunoassay to screen sera and Western blot to confirm reactive samples.
Maple PA; Beard S; Parry RP; Brown KE
Transfusion; 2013 Oct; 53(10 Pt 2):2575-84. PubMed ID: 23721256
[TBL] [Abstract][Full Text] [Related]
8. Detection of human parvovirus 4 viremia in the follow-up blood samples from seropositive individuals suggests the existence of persistent viral replication or reactivation of latent viral infection.
Chen MY; Hung CC; Lee KL
Virol J; 2015 Jun; 12():94. PubMed ID: 26088443
[TBL] [Abstract][Full Text] [Related]
9. Absence of novel human parvovirus (PARV4) in Danish mothers and children.
von Linstow ML; Rosenfeldt V; Lindberg E; Jensen L; Hedman L; Li X; Väisänen E; Hedman K; Norja P
J Clin Virol; 2015 Apr; 65():23-5. PubMed ID: 25766982
[TBL] [Abstract][Full Text] [Related]
10. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.
Sharp CP; Lail A; Donfield S; Simmons R; Leen C; Klenerman P; Delwart E; Gomperts ED; Simmonds P
J Infect Dis; 2009 Oct; 200(7):1119-25. PubMed ID: 19691429
[TBL] [Abstract][Full Text] [Related]
11. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
12. Recombinant ELISA using baculovirus-expressed VP2 for detection of antibodies against canine parvovirus.
Elia G; Desario C; Pezzoni G; Camero M; Brocchi E; Decaro N; Martella V; Buonavoglia C
J Virol Methods; 2012 Sep; 184(1-2):98-102. PubMed ID: 22664182
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response against human bocavirus VP2 virus-like particles.
Lindner J; Karalar L; Zehentmeier S; Plentz A; Pfister H; Struff W; Kertai M; Segerer H; Modrow S
Viral Immunol; 2008 Dec; 21(4):443-9. PubMed ID: 19115933
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human bocavirus-like particles generated by recombinant baculoviruses.
Fang L; Wang Z; Song S; Kataoka M; Ke C; Suzuki T; Wakita T; Takeda N; Li TC
J Virol Methods; 2014 Oct; 207():38-44. PubMed ID: 24992668
[TBL] [Abstract][Full Text] [Related]
15. Parvovirus PARV4 visualization and detection.
Tuke PW; Parry RP; Appleton H
J Gen Virol; 2010 Feb; 91(Pt 2):541-4. PubMed ID: 19846677
[TBL] [Abstract][Full Text] [Related]
16. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
17. Low Prevalence of Parvovirus 4 in HIV-infected Children in Denmark.
Rosenfeldt V; Norja P; Lindberg E; Jensen L; Hedman L; Väisänen E; Li X; Hedman K; von Linstow ML
Pediatr Infect Dis J; 2015 Jul; 34(7):761-2. PubMed ID: 25545184
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
[TBL] [Abstract][Full Text] [Related]
19. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
Pfrepper KI; Enders M; Motz M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):362-5. PubMed ID: 16316402
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of serological assays for detection of Hantaanvirus-specific antibodies in human sera using yeast-expressed nucleocapsid protein.
Petraityte R; Yang H; Hunjan R; Razanskiene A; Dhanilall P; Ulrich RG; Sasnauskas K; Jin L
J Virol Methods; 2008 Mar; 148(1-2):89-95. PubMed ID: 18077007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
